NASEEM ZOJWALLA, M.D.
Vice President, Clinical Development
Dr. Zojwalla joined Peloton Therapeutics as Vice President of Clinical Development in 2015. Previously she was at Onyx Pharmaceuticals, an Amgen subsidiary, where she led the pivotal Phase 3 study for approval of Kyprolis in multiple myeloma. Prior to her experience at Onyx, Dr. Zojwalla led several programs evaluating biologic therapies at ImClone Systems (Eli Lilly) and led oncology Phase 1 clinical trials and contributed to business development acquisitions at Eisai, Inc. Dr. Zojwalla is a board member for the Clayman Institute for Gender Research at Stanford University. A hematologist/oncologist by training, Dr. Zojwalla was previously an assistant clinical professor of medicine at Columbia University Medical Center and a lecturer at the New York University School of Medicine. She received her B.A. degree from Stanford University, an M.D. from Temple University School of Medicine, and completed her hematology/oncology fellowship training at Columbia University.